MCT1 (SLC16A1) and MCT4 (SLC16A3) are overexpressed in patients with GBM compared to non-neoplastic control tissue and WHO grade 3 anaplastic and WHO grade 2 diffuse astrocytoma [41,42,43]. This evidence concerns the gene SLC16A1 and glioblastoma.